Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. by Li, Jing et al.
ARTICLE
Therapeutic targeting of the PLK1-PRC1-axis
triggers cell death in genomically silent childhood
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Chromosomal instability (CIN) is a hallmark of cancer1. Yet, many childhood cancers, such as
Ewing sarcoma (EwS), feature remarkably ‘silent’ genomes with minimal CIN2. Here, we show
in the EwS model how uncoupling of mitosis and cytokinesis via targeting protein regulator of
cytokinesis 1 (PRC1) or its activating polo-like kinase 1 (PLK1) can be employed to induce fatal
genomic instability and tumor regression. We find that the EwS-specific oncogenic tran-
scription factor EWSR1-FLI1 hijacks PRC1, which physiologically safeguards controlled cell
division, through binding to a proximal enhancer-like GGAA-microsatellite, thereby pro-
moting tumor growth and poor clinical outcome. Via integration of transcriptome-profiling
and functional in vitro and in vivo experiments including CRISPR-mediated enhancer editing,
we discover that high PRC1 expression creates a therapeutic vulnerability toward PLK1
inhibition that can repress even chemo-resistant EwS cells by triggering mitotic catastrophe.
Collectively, our results exemplify how aberrant PRC1 activation by a dominant oncogene can
confer malignancy but provide opportunities for targeted therapy, and identify PRC1
expression as an important determinant to predict the efficacy of PLK1 inhibitors being used
in clinical trials.
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Chromosomal instability (CIN) refers to the ongoingacquisition of genomic alterations comprising circum-scribed structural aberrations, deletions of chromosome
arms, translocations, and gains/losses of whole chromosomes3,4.
Through moderate CIN, most cancer types acquire somatic copy
number alterations during each cell division creating intra-tumor
heterogeneity that enhances the overall ‘fitness’ of the cancer cell
population3,4. However, excessive CIN causes non-viable
karyotypes3–5. While CIN-induction in cancers being intrinsi-
cally genomically unstable may have little therapeutic benefit, it
may cause massive cell death in cancers with ‘silent’ or nearly
diploid genomes, such as pediatric cancers including Ewing sar-
coma (EwS)3,6. Indeed, EwS genomes are remarkably silent with
only a few chromosomal gains/losses, but a dominant oncogenic
driver generated through fusions of EWSR1 with variable mem-
bers of the ETS family of transcription factors (in 85% FLI1)7–10.
Thus, we hypothesized that CIN-induction, e.g., by uncoupling
mitosis and cytokinesis11, may constitute a new therapeutic
option for EwS.
Results and discussion
To identify a candidate target offering a large therapeutic window,
we analyzed curated expression data of 929 normal tissue samples
(71 tissue types) and 50 primary EwS tumors12 for cytokinesis-
related genes being highly overexpressed in EwS. As shown in
Supplementary Fig. 1, protein regulator of cytokinesis 1 (PRC1)
exhibited the greatest fold change among 77 significantly over-
expressed cytokinesis-related genes (FDR-adjusted P < 0.05),
being on average ~8-fold higher expressed in EwS than in normal
tissues (Fig. 1a). PRC1 plays pivotal roles in orchestrating cyto-
kinesis through bundling of antiparallel microtubules and for-
mation of the spindle midzone via recruitment of regulator and
effector proteins, such as centralspindlin, the chromosomal pas-
senger complex, kinesins, and polo-like kinase 1 (PLK1)11.
Exploration of a cohort of 196 EwS patients13 uncovered that
high PRC1 expression significantly correlated with poor overall
survival (P= 0.005), which was validated in an independent
cohort of 144 patients at the protein level (P= 0.0037) (Fig. 1b,
c). Multivariate regression analysis of data from the 96 of these
144 patients with complete clinical annotation revealed that
besides metastatic disease at diagnosis, high PRC1 expression was
an independent risk factor (HR= 3.1; P= 0.04) (Supplementary
Data 1).
To test for a potential EWSR1-ETS-dependency of PRC1 in
EwS, we carried out time-course knockdown experiments in A673
EwS cells harboring a doxycycline (Dox)-inducible shRNA
against EWSR1-FLI1 (A673/TR/shEF1). Indeed, knockdown of
EWSR1-FLI1 was associated with a striking reduction of PRC1
transcription, which was confirmed in vivo in xenografted A673/
TR/shEF1 cells (Fig. 2a, b). Such effect was not observed in
xenografts expressing an inducible non-targeting control shRNA
(A673/TR/shCtrl) (Fig. 2b).
Since EWSR1-ETS oncoproteins regulate many of their target
genes through DNA-binding at enhancer-like GGAA-micro-
satellites (mSats)14–18, we analyzed available DNase-Seq and
ChIP-Seq data from EwS cell lines (A673, SK-N-MC)15,19 for
EWSR1-FLI1 and histone marks (H3K4me1, H3K27ac). We
found a prominent EWSR1-FLI1 signal located ~90 kb telomeric
from the PRC1 promoter that mapped to a GGAA-mSat within
open chromatin (DNase 1 hypersensitivity site) (Fig. 2c). In both
cell lines, silencing of EWSR1-FLI1 was accompanied by a loss of
EWSR1-FLI1 signals at this locus, and, more interestingly, with a
loss of H3K27 acetylation usually marking active enhancers
(Fig. 2c). The EWSR1-FLI1-dependent enhancer activity of this
GGAA-mSat was confirmed in reporter assays in A673/TR/
shEF1 cells with/without silencing of EWSR1-FLI1 (Fig. 2d). Since
GGAA-mSats are typically polymorphic, we tested several cloned
fragments (1053 bp including flanking regions) from three
Fig. 1 PRC1 is overexpressed in EwS and correlates with poor overall survival. a Analysis of PRC1 mRNA expression in 50 EwS and 929 normal tissues
(comprising 71 normal tissue types). Data are represented as box plots. Horizontal bars indicate median expression levels, boxes the interquartile range,
and whiskers the 10th and 90th percentile. Two-sided Mantel-Haenszel test. b Kaplan-Meier survival analysis of 196 EwS patients stratified by thirds of
PRC1mRNA expression (Low, Moderate, High). Two-sided Mantel-Haenszel test. c Left: IHC staining of a TMA comprising 144 EwS tumors for PRC1. Scale
bar= 100 µm. Right: Kaplan-Meier analysis of overall survival of 144 EwS patients stratified by their intra-tumoral PRC1 expression levels (Low: IRS < 2;
Moderate: IRS 2–5; High: IRS > 5). Two-sided Mantel-Haenszel test.
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different EwS cell lines that had different numbers of consecutive
GGAA-repeats at this locus (A673, on average 14 repeats [14/14];
EW1, on average 12 repeats [13/11]; TC71, on average 10.5
repeats [11/10]). We noted a strong gain of enhancer activity with
increasing numbers of consecutive GGAA-repeats (Fig. 2d),
which has been previously described for other GGAA-mSats to
contribute to inter-tumor heterogeneity in EwS17,18. Another
genetic variation in the cloned fragments was excluded by whole-
genome sequencing and focal Sanger-sequencing. Notably, the
average number of GGAA-repeats at this mSat corresponded to
the PRC1 expression levels across EwS cell lines at both the
mRNA and protein levels (Supplementary Fig. 2b). Consistently,
analysis of publicly available proteomics data (https://
depmap.org/portal/) comprising 4 EwS cell lines including
TC71 and A673 showed that TC71 exhibited the lowest and A673
the highest PRC1 protein levels (Supplementary Fig. 2c).
To confirm the regulatory effect of this GGAA-mSat on PRC1
transcription, we carried out clustered regulatory interspaced
Fig. 2 PRC1 is a direct EWSR1-FLI1 target gene. a Time-course knockdown of EWSR1-FLI1 in A673/TR/shEF1 EwS cells harboring a Dox-inducible shRNA
against EWSR1-FLI1 and analysis of PRC1 and EWSR1-FLI1 expression by qRT-PCR in vitro. Dots represent means and whiskers SEM, n= 4 biologically
independent experiments. b Analysis of PRC1 expression by IHC in xenografts derived from A673/TR/shEF1 and A673/TR/shCtrl cells with/without Dox-
treatment for 96 h in vivo. Data are displayed as individual dots. Horizontal bars represent the median, n indicates the number of biologically independent
experiments/cell line: A673/TR/shCtrl n= 9, A673/TR/shEF1 n= 5; scale bar= 200 µm. c Integrative genomics view (hg19) of the PRC1 locus from data
of A673 and SK-N-MC cells being transfected with shRNAs targeting either GFP (shGFP; negative control) or EWSR1-FLI1 (shEF1). d Luciferase reporter
assays in A673/TR/shEF1 cells with/without knockdown of EWSR1-FLI1 (Dox+/−) 72 h after transfection. Data are displayed as individual dots. Horizontal
bars represent means and whiskers SEM, n= 6 biologically independent experiments. e Analysis of PRC1 expression by qRT-PCR (left) and viable cells
(right) in TRE-regulated dCas9-KRAB A673 and RDES cells transduced with sgRNAs against the PRC1-associated GGAA-mSat and GFP sgRNAs (negative
control) 15d after addition of Dox (2 µg/ml). Data are displayed as individual dots. Horizontal bars represent means and whiskers SEM, n= 6 biologically
independent experiments. f Analysis of PRC1 expression by qRT-PCR (left) and viable cells (right) in wildtype (wt), CRISPR Cas9-edited negative control
(NC), and CRISPR Cas9-initiated HDR edited (insertion of 24-GGAA-repeats) A673 cells 72 h after seeding. Data are displayed as individual dots.
Horizontal bars represent means and whiskers SEM, n= 8 biologically independent experiments. g Relative crosslinking frequencies observed in CRISPR
Cas9-initiated HDR edited PRC1-associated GGAA-mSat knockout (KO) A673 EwS cells are shown in gray and insertion of 24-GGAA-repeats in dark red.
Gray shading indicates the position and size of the analyzed fragments, and red shading the ‘vantage point’ fragment harboring the PRC1-associated GGAA-
mSat. The highest crosslinking frequency value in the graph was normalized and set to 1 in each replicate. Data are mean and SEM, n= 4 biologically
independent experiments. Two-sided Mann-Whitney test in all panels.
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short palindromic repeats interference (CRISPRi) experiments in
two EwS cell lines (A673, RDES). Epigenetic interference with this
GGAA-mSat markedly reduced PRC1 expression and prolifera-
tion of derivative EwS cells (A673/TRE/dCas9/KRAB; RDES/
TRE/dCas9/KRAB) (Fig. 2e). The relationship between PRC1 and
this GGAA-mSat was further probed by CRISPR Cas9-initiated
homologous deficiency repair (HDR) DNA editing. To avoid
knocking out PRC1 itself, which may have led to unphysiologi-
cally low or absent PRC1 expression levels, we chose to knockout
(KO) its associated enhancer-like GGAA-mSat. Similar to
CRISPRi, the genetic knockout (KO) of the PRC1-associated
GGAA-mSat was accompanied by significantly lower PRC1
expression levels, proliferation, and sphere-formation in both cell
lines (Supplementary Fig. 2d–h). Conversely, replacement of the
wildtype mSat comprising 14 consecutive GGAA-repeats by a
‘longer’ haplotype (24 GGAA-repeats) significantly increased
PRC1 expression, proliferation, and sphere-formation (Fig. 2f,
Supplementary Fig. 2g, h). To elucidate whether PRC1 was
directly regulated by EWSR1-FLI1, we performed chromosome
conformation capture (3C)-PCR assays in A673 cells with either a
KO or genetically elongated PRC1-associated GGAA-mSat. These
experiments confirmed a physical interaction of both DNA ele-
ments, which was abrogated by KO of the PRC1-associated
GGAA-mSat (Fig. 2g, Supplementary Fig. 2i). In synopsis, our
results indicated that PRC1 is a direct EWSR1-FLI1 target whose
high but variable expression is controlled by EWSR1-FLI1-
binding to a polymorphic enhancer-like GGAA-mSat.
To explore the functional role of PRC1 in EwS, we generated
three EwS cell lines (RDES, SK-N-MC, TC32) with Dox-inducible
shRNAs against PRC1 (shCDS/shUTR) and non-targeting con-
trols (shCtrl). Knockdown efficacy was confirmed by qRT-PCR
and western blotting (Supplementary Fig. 3a, b). We first carried
out transcriptome profiling of two of these EwS cell lines (RDES,
SK-N-MC) after Dox-induced PRC1 silencing (Supplementary
Data 2). Functional gene-set enrichment followed by weighted
correlation network analysis revealed that PRC1 had pleiotropic
effects on diverse cellular functions linked amongst others to
DNA packaging, chromosome formation, cell morphology, and
growth (Fig. 3a, Supplementary Fig. 3c). In line with these pre-
dictions, we noted that Dox-induced PRC1 silencing strongly
reduced cell proliferation while inducing apoptosis in all three cell
lines (Fig. 3b, c). Similarly, PRC1 knockdown decreased clono-
genic capacity and anchorage-independent growth in vitro and
strongly inhibited tumor growth in vivo (Fig. 3d, e, Supplemen-
tary Fig. 3d, e). Immunohistological assessment of the xenografts
confirmed that PRC1 was efficiently downregulated, which was
associated with a significantly reduced Ki-67 positivity from
~80% down to ~30%, but ~8-fold higher rates of apoptosis
(cleaved caspase-3) (Fig. 3f). Notably, although PRC1 knockdown
appeared to strongly reduce tumor growth, the remaining pro-
liferation rate of the tumor cells was still relatively high compared
to other malignancies, such as breast cancer (for review see
ref. 20), suggesting that the massive induction of apoptosis rather
than the mere blockage of mitotic activity was the main driver of
reduced tumor growth.
Based on PRC1’s essential function in spindle midzone
formation11, we reasoned that these phenotypes may be explained
by excessive CIN resulting from cytokinesis defects upon PRC1
knockdown. Indeed, cell cycle analysis of synchronized EwS cells
showed that PRC1 silencing led to a higher fraction of cells in the
G2/M phase over time, which is indicative of a delayed transition
through the G2/M-phase that may contribute to the generation of
tetraploid cells (Supplementary Fig. 3f). Fluorescence-in-situ-
hybridization (FISH) analyses using pan-centromere probes
revealed that PRC1 knockdown for only 48 h induced likely non-
viable chromosomal abnormalities in ~70% of EwS cells
compared to ~10% in controls (Fig. 3g). Moreover, time-lapse
live-cell imaging of TC32 and RDES EwS cells with/without PRC1
knockdown demonstrated that PRC1 silencing was associated
with a significantly higher number of cells exhibiting mitotic
activity without subsequent cytokinesis resulting in chromosome
missegregation in both cell lines (P= 0.0022) (Fig. 3h, Supple-
mentary Fig. 3g). These in vitro observations corresponded to a
higher degree of nuclear pleomorphism and the presence of so-
called, ‘monster’ cells with bizarre, aneuploid, and often multi-
lobulated nuclei, as well as to higher rates of DNA double-strand
breaks as indicated by γ-H2AX stains in vivo (Fig. 3i, j). The
human origin of monster cells was validated by immunohis-
tochemistry (IHC) using a human-specific anti-mitochondrial
antibody (Fig. 3i). In sum, these results indicated that PRC1 is
essential for proper cell division in EwS and that disruption of the
delicate balance between mitosis and cytokinesis causes non-
viable karyotypes in this otherwise genetically silent pediatric
cancer.
Based on these results, we hypothesized that targeting cyto-
kinesis may offer a new therapeutic strategy for EwS. Since––to
the best of our knowledge––there are no direct inhibitors against
PRC1 available, we explored whether targeting its major upstream
interacting partner PLK1 could serve as an alternative target.
Indeed, PLK1 phosphorylates and binds to PRC1, which enables
the formation of the PLK1-PRC1 complex that is critical for its
translocation to the central spindle to initiate cytokinesis11,21,22.
In accordance, both genes were highly significantly co-expressed
in patient EwS tumors (n= 196, rPearson= 0.58, P= 2.2−16)
(Supplementary Fig. 4a), and combining both markers yielded a
highly significant association with worse overall survival
(P= 0.0013) (Supplementary Fig. 4b, c). Thus, we treated our
EwS models with two small-molecule ATP-competitive PLK1
inhibitors (BI2536, BI6727 [alias Volasertib]) that are currently
used in clinical trials (Supplementary Data 3). Both inhibitors
showed strong anti-proliferative effects on EwS cells at lower
nanomolar levels in vitro (Fig. 4a, b). Even more strikingly, direct
and indirect downregulation of PRC1 either by RNA interference
or genetic KO of the PRC1-associated GGAA-mSat dramatically
diminished the sensitivity of EwS cells toward both PLK1 inhi-
bitors (Fig. 4a, b). Conversely, upregulation of PRC1 via CRISPR-
mediated elongation of the PRC1-associated GGAA-mSat sig-
nificantly increased their sensitivity toward both inhibitors
(Fig. 4b). Importantly, it should be noted that the percentage of
viable cells at the time of the beginning of PLKi-treatment was
~90–95% and that the percentage of apoptotic cells was equal in
the control and treatment groups (Supplementary Fig. 4d, e).
Similar to long-term suppression of PRC1, long-term treatment
of EwS cells with both inhibitors strongly reduced clonogenic and
anchorage-independent growth, and significantly induced apop-
tosis (Fig. 4c, d, Supplementary Fig. 4f). Together, these findings
suggested that EwS cells with high PRC1 expression are very
sensitive to PLK1 inhibition and that this sensitivity can be almost
abolished by the suppression of PRC1.
To confirm the PRC1-dependency of PLK1 inhibition in vivo,
we used our CRISPR Cas9-initiated HDR edited A673 EwS cells
and xenografted them in NOD/scid/gamma (NSG) mice. Once
tumors were palpable, mice were treated with BI2536 (40 mg/kg)
or BI6727 (30 mg/kg) once per week via tail vein injection at
clinically achievable dosages (Supplementary Data 4). Treatment
of mice xenografted with highly PRC1 expressing EwS cells led to
strong inhibition of tumor growth and even tumor regression
after only three cycles of treatment without overt adverse effects,
such as weight loss (Fig. 4e, f, Supplementary Fig. 4g, h). In
addition, both PLK1-inhibitors led to a significant increase in the
number of aneuploid cells and, monster’ cells (Supplementary
Fig. 4i). Strikingly, this effect could be abrogated by genetic KO of
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Fig. 3 PRC1 safeguards genome stability in EwS cells. a Transcriptomic network analysis after PRC1 knockdown. b Cell viability 72 h after PRC1 silencing.
Data are displayed as individual dots. Horizontal bars represent means and whiskers SEM, n= 6 biologically independent experiments; two-sided Mann-
Whitney test. c Analysis of apoptosis (summary of both shPRC1). Data are displayed as individual dots. Horizontal bars represent means and whiskers
SEM, n= 6 biologically independent experiments; two-sided Mann-Whitney test. d Sphere-formation after PRC1 knockdown. Data are displayed as
individual dots. Horizontal bars represent means and whiskers SEM, n= 9 biologically independent experiments; two-sided Mann-Whitney test.
Representative images; scale bar= 50 µm. e The volume of xenografts with/without PRC1 silencing. Data are mean and SEM, n indicates the number of
animals per condition: n= 5 shCtrl and n= 6 shCDS/shUTR in both cell lines. Two-sided Mann-Whitney test. f Representative micrographs and
quantifications of PRC1 (IRS), Ki-67, and cleaved caspase-3 (CC3). Data are displayed as individual dots. Horizontal bars represent median IRS of PRC1 or
means and whiskers SEM for positivity, respectively; the number of animals per condition is as in e; two-sided Mann-Whitney test; scale bar= 100 µm. g
Representative images (scale bar= 1 µm) and quantification of aberrant metaphases. Horizontal bars represent means and whiskers SEM, n= 6
biologically independent experiments. Parentheses indicate a total number of analyzed mitoses (summary of both shPRC1). Two-sided Chi-squared test. h
(Left) Time-lapse images of TC32 cells with/without PRC1 knockdown. F-actin (red), DNA (blue). Arrows=merged nuclei. Scale bar= 10 µm. (Right)
Quantification of cytokinesis failure (summary of both shPRC1). Data are displayed as individual dots. Horizontal bars represent means and whiskers SEM;
n= 6 biologically independent experiments. i Representative micrographs of xenografts (H&E, human mitochondria (mt)), and quantification of, monster’
cells per low-power field (LPF). Data are displayed as individual dots. Horizontal bars represent means and whiskers SEM, the number of animals per
condition is as in e; two-sided Mann-Whitney test; scale bar= 20 µm. j Representative micrographs for γ-H2AX, and quantification per HPF. Data are
displayed as individual dots. Horizontal bars represent means and whiskers SEM, the number of animals per condition is as in e; two-sided Mann-Whitney
test; scale bar= 100 µm.
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the PRC1-associated enhancer-like GGAA-mSat (Supplementary
Fig. 4h, i). Remarkably, mice with total tumor regression did not
show any sign of tumor recurrence up to 25 days after the last
cycle as confirmed by necropsy and IHC (Supplementary Fig. 4j,
k). In contrast, xenografts from A673 EwS cells with KO of the
PRC1-associated GGAA-mSat exhibited delayed tumor growth
and only progressive disease during treatment despite a 4th
injection was administered (Fig. 4f, Supplementary Fig. 4h, i).
Together, these findings suggested that genomically silent
pediatric cancers, such as EwS, may be very sensitive to PLK1
Fig. 4 High PRC1 expression levels prime EwS cells for PLK1 inhibition. a Heatmaps depicting the average percentage of growth inhibition in EwS cells
with/without PRC1 silencing after 72 h of PLK1 inhibition; n= 6 biologically independent experiments. b Analysis of IC50 in CRISPR Cas9-edited A673 cells
after 72 h of PLK1 inhibition. Data are displayed as individual dots. Horizontal bars represent means and whiskers SEM, n= 6 biologically independent
experiments. c Sphere-formation of EwS cells treated with BI2536 or BI6727. Data are displayed as individual dots. Horizontal bars represent means and
whiskers SEM, n= 9 biologically independent experiments. Representative images are shown; scale bar= 50 µm. d Analysis of apoptosis of EwS cells with/
without PLK1 inhibition for 72 h. Data are displayed as individual dots. Horizontal bars represent means and whiskers SEM, n= 6 biologically independent
experiments. e Schematic of PLK1 inhibitor treatment in vivo. f Individual tumor volume curves (n= 6 per condition for NC-cells, n= 7 per condition for
KO-cells). Representative micrographs of H&E and PRC1, the positivity of cleaved caspase-3 (CC3), as well as γ-H2AX per HPF. Scale bar= 100 µm. g
Excess over Bliss analysis of RDES cells with/without PRC1 knockdown treated with combinations of Vincristine (VCR) and the PLK1 inhibitors in vitro (red
indicates synergy). Summary level (mean) data from n= 6 biologically independent experiments. h Analysis of tumor volume of mice treated with either
vehicle, VCR (1 mg/kg/d, i.p.) alone, BI6727 (5 mg/kg, i.v.) alone, or in combination. Representative micrographs of PRC1 staining and positivity of γ-
H2AX, CC3, and Ki-67 per HPF. n= 6 biologically independent animals per condition. Scale bar= 100 µm. i Dose-response curves of two Doxorubicin
(Doxo)-resistant EwS cell lines (A673, TC71) treated with Doxo combined with BI2536 or BI6727 for 72 h. The reverse index (RI) is given. Dots represent
means and whiskers SEM, n= 6 biologically independent experiments. j Median effective dose (ED50) for Doxo-treatment alone or in combination with
PLK1 inhibitor BI2536 or BI6727 for 72 h in Doxo-resistant A673 and TC71 cells. Data are displayed as individual dots. Horizontal bars represent means and
whiskers SEM, n= 6 biologically independent experiments. k Schematic illustrating key findings of this study. Two-sided Mann-Whitney test in all panels.
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inhibition in case of high PRC1 expression. In support of this
notion, analysis of matched in vivo gene expression and drug
response data from pediatric tumor types (including EwS)23 with
relatively silent genomes revealed that good responses to BI6727
(Volasertib) were observed exclusively among PRC1 high
expressing xenografts (defined by median expression; P= 0.0325,
Fisher’s exact test)—an effect not observed for PLK1 and MKI67
(Supplementary Data 5). However, since this dataset contained
xenografts from only 4 different EwS cell lines, we extended our
analyses using publicly available drug-response and gene
expression data from the DepMap project, comprising 11 EwS
cell lines (https://depmap.org). In this dataset, we observed a
relatively strong negative correlation (rPearson= –0.54) of PRC1
mRNA levels with lower cell viability upon Volasertib treatment
(P= 0.04) (Supplementary Data 6). This correlation even
remained significant when focusing on the 9 of 11 EwS cell lines
that exhibited a confirmed EWSR1-FLI1 fusion (rPearson= –0.72,
P= 0.02) (Supplementary Fig. 4l). Similar to our observations
made in the in vivo dataset (Supplementary Data 5)23, such
correlations were neither observed for PLK1 nor MKI67 regard-
less of the EWSR1-FLI1 status (PLK1: rPearson= –0.19/–0.4,
P= 0.29/0.14; MKI67: rPearson= 0.04/–0.09, P= 0.46/0.41) (Sup-
plementary Data 6).
In the clinical setting, Vincristine (VCR) and Doxorubicin
(Doxo) are highly active chemotherapeutics employed in first-line
treatment and relapsed EwS10. Hence, we assessed the potential
synergistic effects of PLK1 inhibition with both drugs. As shown
in Fig. 4g, the microtubule-destabilizing drug VCR showed highly
synergistic effects (positive Bliss score) at nanomolar concentra-
tions in RDES cells, which was strongly diminished upon PRC1
knockdown. This PRC1-dependent effect was confirmed in TC32
EwS cells (Supplementary Fig. 5a) and corresponded to prior
observations of the synergy of BI6727 with VCR in this cell line24.
This combination therapy also significantly reduced the necessary
IC50 of PLK1 inhibitors (Supplementary Fig. 5b), which may help
to mitigate their potential adverse effects. It should be noted that
almost identical effects on the PRC1-dependent PLK1 efficacy
were observed in TC32 and RDES cells (Fig.4g, Supplementary
Fig. 5a), which differ in their STAG2 and TP53 mutation status
(TC32: STAG2-mut/TP53-wt; RDES: STAG2-wt/TP53-mut)7,8,
suggesting that both mutations have likely no impact on the
efficacy of PLK1 inhibition in EwS cells, although it has been
reported that PLK1 can phosphorylate STAG1/225,26. Along the
same lines, there was no statistically significant overlap between
STAG2-mutated or TP53-mutated and PRC1 highly expressing
patient EwS tumors (Supplementary Data 7). Similar to the
in vitro findings, we noted a strong synergistic effect of BI6727
and VCR in vivo, even when applying a 6-fold reduced dose of
BI6727 (now 5mg/kg) as inferred from our in vitro synergy
assays (Supplementary Fig. 5c). In fact, while VCR or BI6727 (at
the reduced dose) as single agents only delayed tumor growth, a
combination of both drugs led to tumor regression in all mice
without adverse effects, such as weight loss (Fig. 4h, Supple-
mentary Fig. 5d, e). However, such a synergistic effect was not
observed for the intercalating drug Doxo across both cell lines
and PLK1 inhibitors regardless of the PRC1 levels (Supplemen-
tary Fig. 6a). Yet, it is noteworthy that both PLK1 inhibitors were
still effective at nanomolar concentrations in EwS cell lines being
highly resistant to Doxo (Supplementary Fig. 6b), and that they
could partially restore their Doxo-sensitivity (Fig. 4i, j).
Collectively, our results demonstrate that the EWSR1-FLI1-
mediated high PRC1 expression sensitizes EwS cells for PLK1
inhibition, and renders PRC1 as a promising predictive bio-
marker for therapies evoking cytokinesis defects and mitotic
catastrophe (Fig. 4k). We anticipate that CIN-directed therapies
have the potential to profoundly affect clinical outcomes,
especially in cancers with largely silent genomes, such as EwS.
Still, careful biomarker-guided selection of patients is required to
identify those patients who may benefit in particular from ther-
apeutic modulation of CIN. In this regard, PLK4 inhibition was
recently recognized as a therapeutic treatment option specifically
for TRIM37-amplified neuroblastoma and breast cancer via
causing centromere-dysfunction27,28. Notably, our data may also
shed new light on why previous preclinical testing of PLK1
inhibition in non-preselected EwS models may have yielded
heterogeneous results on its efficacy23. In fact, especially the TC71
cell line used in this screen exhibited a relatively low response
toward BI6727 and the lowest PRC1 expression levels among all
four cell lines tested in vivo23 (Supplementary Data 5). These
findings correspond to the rather low PRC1 expression levels and
short PRC1-associated GGAA-mSat of the TC71 cell line as
demonstrated in this study (Supplementary Fig. 2b). Yet, it should
be noted that the interaction of PLK1 and PRC1 is complex:
While PRC1 phosphorylation by PLK1 is required for the for-
mation of the PRC1-PLK1 protein complex and its translocation
to the spindle midzone, it has been reported that PLK1 can also
negatively regulate PRC1 to prevent premature midzone forma-
tion before cytokinesis29. In turn, microtubules can stimulate
PRC1 phosphorylation by PLK1, creating a potential negative
feedback loop controlling PRC1 activity29. These facts imply that
PRC1 highly expressing cells may have adapted by increasing
PLK1 to dampen the effects of high PRC1, which would be in
agreement with our finding that PRC1 and PLK1 are significantly
co-expressed in patient EwS tumors (Supplementary Fig. 4a).
Accordingly, it is tempting to speculate that when PLK1 is
inhibited, the PRC1 function may become deregulated and toxic
to the cell. Although this is subject to future research, it is con-
ceivable that the PRC1-related mechanism identified in our EwS
model may be translatable to other cancers for which immuno-
histochemical detection of high PRC1 levels could serve as a
broadly available, and inexpensive predictive biomarker.
Methods
The provenience of cell lines and cell culture conditions. Human cell lines were
provided by the following repositories and/or sources: A673, HEK293T, and RDES
cells were purchased from ATCC. SK-N-MC was provided by the German Col-
lection of Microorganism and Cell Cultures (DSMZ). TC71 and TC32 cells were
kindly provided by the Children’s Oncology Group (COG). A673/TR/shEF1 cells
were described previously30. EW1 cells were kindly provided by O. Delattre
(Institut Curie Research Center, Paris, France). All cell lines were cultured in
RPMI-1640 medium with stable glutamine (Biochrom) supplemented with 10%
tetracycline-free fetal calf serum (FCS; Sigma-Aldrich) and 100 U/ml penicillin and
100 µg/ml streptomycin (Merck) at 37 °C with 5% CO2 in a humidified atmo-
sphere. Cell lines were routinely tested for mycoplasma contamination by nested
PCR, and cell line identity was regularly verified by STR-profiling. Doxorubicin-
resistant (Doxo-res) EwS cells were established through continuous culture with
serially increasing Doxo concentrations starting at ~10 nM corresponding to pre-
determined IC50 values. After successful adaptation to the given concentrations
indicated by re-growth, cells were cultured with serially ascending Doxo con-
centrations by multiplying the IC50 values by factor 1.1–2.0. Doxo-res variants
were maintained with ~200 nM Doxo.
RNA extraction, reverse transcription, and quantitative real-time PCR (qRT-
PCR). Total RNA was isolated using the NucleoSpin RNA kit (Macherey-Nagel).
One microgram of total RNA was reverse-transcribed using a High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). qRT-PCR reactions (final
volume 20 µl) were performed using SYBR Green Mastermix (Applied Biosystems)
mixed with diluted cDNA (1:10) and 0.5 µM forward and reverse primer on a
BioRad CFX Connect instrument and analyzed using BioRad CFX Manager
3.1 software. Gene expression values were calculated using the ΔΔCt method
relative to the housekeeping gene RPLP0 as an internal control. Oligonucleotides
were purchased from MWG Eurofins Genomics (Ebersberg, Germany) (Supple-
mentary Data 8). Thermal conditions for qRT-PCR: heat activation at 95 °C for
2 min, DNA denaturation at 95 °C for 10 s, annealing and elongation at 60 °C for
20 s (50 cycles), final denaturation at 95 °C for 30 s.
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Analysis of published DNase sequencing (DNase-Seq) and chromatin
immunoprecipitation followed by high-throughput DNA sequencing (ChIP-
Seq) data. ENCODE SK-N-MC DNase-Seq (GSM736570) and ChIP-Seq data
(GSE61944) were downloaded from the GEO, processed as previously described16,











Cloning of GGAA-mSats and luciferase reporter assays. To assess the average
enhancer activity of both alleles of the PRC1-associated GGAA-mSat in a given cell,
1053 bp fragments (hg19 coordinates: chr15:91,623,953–91,625,005) including
PRC1-associated GGAA-mSats (hg19 coordinates: chr15:91,624,412–91,624,459)
(Supplementary Fig. 2a) from three EwS cell lines (A673, EW1, TC71) were PCR-
cloned upstream of the SV40 minimal promoter into the pGL3-Fluc vector (Pro-
mega, #E1761). Primer sequences are given in Supplementary Data 8. The presence
of additional variants devoid of the GGAA-mSat was ruled out by whole-genome
sequencing of the parental cell lines and Sanger-sequencing of the cloned frag-
ments. A673/TR/shEF1 cells (2 × 105 per well) were co-transfected with both alleles
of the mSat-containing pGL3-Fluc vectors of a given cell line in equal mass and
with the Renilla pGL3-Rluc vectors (Promega) (ratio 100:1) in a six-well plate with
2 ml of growth medium. Transfection medium was replaced by medium with/
without Doxycycline (Dox) (1 μg/ml; Sigma-Aldrich) 4 h after transfection. After
72 h the cells were lysed and assayed with a dual luciferase assay system (Berthold).
Firefly luciferase activity was normalized to Renilla luciferase activity.
CRISPR interference. The pLKO.1-puro U6 sgRNA BfuAI large stuffer lentiviral
backbone for expression of the sgRNAs and the pHAGE TRE dCas9-KRAB len-
tiviral plasmid31 encoding dCas9-KRAB were obtained from Addgene (#52628 and
#50917). Candidate sgRNAs were identified by searching for G(N)20GG motifs 150
bases upstream/downstream of the PRC1-associated GGAA-mSat that correspond
to the nucleotide requirements for U6 Pol III transcription and the spCas9 PAM
recognition element (NGG) (Supplementary Data 8)32. Relevant off-target matches
were determined and ruled out by CRISPR-Cas9 guide RNA design checker (IDT).
SgRNAs were then cloned individually into BfuAI sites in the pLKO.1-puro
U6 sgRNA BfuAI large stuffer plasmid and verified by Sanger-sequencing. Lenti-
viral particles were produced in HEK293T packaging cells by transfection of the
lentiviral expression plasmid along with psPAX2 (Addgene #12260) and pMD2.G
(Addgene #12259) packaging plasmids. 48 h post-transfection, the lentivirus-
containing medium was harvested and concentrated using the Lenti-X con-
centrator solution (Clontech). The A673 and RDES dCas9-KRAB stable EwS cell
lines were generated by infecting the cell lines with pHAGE TRE dCas9-KRAB
lentivirus in combination with G418 selection (800 µg/ml). A673 and RDES cells
stably expressing dCas9-KRAB were transduced with pLKO.1-sgRNA lentiviral
particles and treated with puromycin (1 µg/ml) and G418 (400 µg/ml) to select and
maintain stable cell lines. After selection, cells were left untreated or induced with
Dox (2 µg/ml) for 14 d with regular media changes. PRC1 expression levels were
analyzed by qRT-PCR and cell viability was assessed by standardized cell counting
in hemocytometers using the Trypan-blue (Sigma-Aldrich) exclusion method. A
sgRNA targeting the GFP gene was used as the negative control.
Homology-directed repair (HDR) using Alt-R CRISPR-Cas9 system and
ultramer oligos. We used the publicly available gRNA design tool from IDT
(https://eu.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM) to identify
high-scoring candidates gRNAs to two target regions flanking the PRC1-associated
GGAA-mSat motifs (Supplementary Data 8). Each crRNA (CRISPR RNA) (IDT,
Alt-R CRISPR-Cas9 crRNA, custom design) was mixed with tracrRNA (trans-
activating crRNA) (IDT, Alt-R CRISPR-Cas9 tracrRNA) in equimolar concentra-
tions to form crRNA:tracrRNA duplexes (10 µM). The upstream and downstream
RNA complexes were mixed in equimolar concentrations and then incubated with
Cas9 HIFI V3 nuclease (IDT, Alt-R S.p. HiFi Cas9 Nuclease V3, #369268) for
5 min at room temperature (RT) to assemble the RNP complex33. A negative
control (ctrl) ctRNP was established at the same time (IDT, Alt-R Cas9 Negative
Control). Ultramer ssODN donor of either homologous arms alone (50 bp
upstream and downstream) or homologous arm plus a 24-GGAA-insert (196 bp)
was added to the RNP complex individually and incubated for 5 min at RT to
generate the RNP mixture (ssODN final concentration 4 µM). The RNP mixture
was added to a diluted CRISPR MAX reagent (Invitrogen) to generate the RNP
lipid complex of a final concentration of 90 nM. The ctRNP transfection solution
was then incubated for 13 min at RT. A673 and RDES EwS cells were synchronized
in the G2/M phase via incubation with Nocodazole for 16 h (200 ng/ml) followed
by a 1 h release before transfection. 50 µl of the ctRNP transfection solution were
added to 100 µl synchronized cell suspension (40,000 cells) with HDR enhancer
(final concentration 30 µM) (IDT, Alt-R® HDR Enhancer) seeded in triplicates in
96-well plates. Transfected cells were incubated at 37 °C (5% CO2) and the medium
from cells was replaced by a fresh medium without HDR enhancer after 24 h.
Genomic DNA isolation and detection of editing efficacy at a bulk level were
performed 48 h after transfection by assessment of the fluorescence intensity and
by PCR amplification and gel electrophoresis. Finally, single-cell cloning was car-
ried out to select successfully edited clones, which were verified by Sanger-
sequencing (Supplementary Fig. 2d).
Chromatin conformation capture (3C) PCR assays. The 3C procedure was
performed according to established protocols34,35 with minimal modifications.
Briefly, 1 × 107 cells were treated with 1% formaldehyde in phosphate-buffered
saline (PBS)/10% FCS and incubated for 10 min at RT while tumbling, and then
this cross-linking reaction was quenched by the addition of glycine to 0.125 M.
After washing with PBS, the fixed cells were incubated for 15 min in an ice-cold
lysis solution (10 mM Tris, pH 8.0, 10 mM NaCl, 0.2% NP40 and a protease
inhibitor cocktail [Roche]) under constant shaking. The formaldehyde-crosslinked
nuclei were harvested and washed with 1.2× RE buffer (50 mM potassium acetate,
20 mM tris acetate [pH 7.9], 10 mM magnesium acetate, 100 µg/ml bovine serum
albumin [BSA]) and then re-suspended into 0.5 ml 1.2× RE buffer with the
addition of sodium dodecyl sulfate (SDS) to the final concentration of 0.3%. After
incubation for 20 min at 65 °C followed by 40 min at 37 °C with shaking at
1200 rpm, Triton X-100 was added to a final concentration of 2% and the solution
was further incubated for 1 h at 37 °C with shaking at 1200 rpm to sequester the
SDS. The DNA was first digested with 400U HindIII-HF (NEB) for 6 h at 37 °C
with shaking followed by the addition of another 400U HindIII-HF for overnight
digestion at 37 °C with shaking at 1200 rpm. The restriction endonuclease was
inactivated by the addition of SDS to a final concentration of 1.6% and incubation
for 20 min at 65 °C under shaking at 1200 rpm. After collection of the digested
solution, the solution was diluted in 7 ml 1× ligation buffer (30 mM Tris-HCI [pH
7.8], 10 mM MgCI2, 10 mM DTT, 1 mM ATP, and 100 µg/ml BSA). Then, Triton
X-100 was added to a final concentration of 1%, and the solution was incubated at
37 °C for 1 h while gently shaking. Next, 100U of T4 DNA Ligase (HC) (Promega)
was added, and the DNA was ligated for 4 h at 16 °C and then for 30 min at RT.
Crosslinks were reversed by incubating the sample at 65 °C overnight in the pre-
sence of 300 µg proteinase K. A total of 300 µg RNase A was added and incubated
for 45 min at 37 °C. DNA was purified by extraction with phenol, phenol-
chloroform, and chloroform followed by precipitation with ethanol and dissolved
in 100 µl of 10 mM Tris (pH 7.5). Digestion efficiencies were monitored by SYBR
qPCR with primer pairs that amplify genomic regions containing or devoid of
HindIII digestion sites (Supplementary Fig. 2i). The ligation products were ana-
lyzed by TaqMan real-time PCR (Supplementary Data 8). A random ligation
control was generated using a bacterial artificial chromosome (BAC; clone CH17-
26I20, CHORI BACPAC Resources Center) harboring all ligation products under
study. Thirty micrograms of BAC clone were digested with HindIII-HF (NEB) and
then ligated at a high DNA concentration, and extracted by phenol, phenol-
chloroform, and chloroform followed by precipitation with ethanol. After diges-
tion, cross-links were reversed, and DNA was purified. The DNA was serially
diluted and used to generate a standard curve to which all 3C products were
normalized. The ligation frequency was determined as a ratio of the 3C ligation
product to the corresponding product in the random ligation control. For further
normalization, the frequencies of ligation between fragments of the locus of
ERCC3, a ubiquitously expressed gene, were determined34.
Generation of Dox-inducible short hairpin RNA (shRNA) expressing cells. For
long-term experiments, human EwS cell lines RDES, SK-N-MC, and TC32 were
transduced with lentiviral pLKO-TET-ON all-in-one vector system (Plasmid
#21915, Addgene) containing a puromycin resistance cassette for Dox-inducible
expression of shRNAs against PRC1 (shPRC1) or a non-targeting control shRNA
(shCtrl). Dox-inducible vectors were generated according to a publicly available
protocol36 using In-Fusion HD Cloning Kit (Clontech) containing as insert a non-
targeting shRNA (shCtrl), and two shRNAs against PRC1 (Supplementary Data 8).
Vectors were amplified in Stellar Competent Cells (Clontech) and integrated
shRNA was verified by Sanger-sequencing (sequencing primer: 5′-GGCAGGGA-
TATTCACCATTATCGTTTCAGA-3′). Lentiviral particles were generated in
HEK293T cells. Virus-containing supernatant was collected to infect the human
EwS cell lines. Successfully infected cells were selected with 2 µg/ml puromycin
(InVivoGen). The shRNA expression for PRC1 knockdown in EwS cells was
achieved by adding 1 µg/ml Dox every 48 h to the medium. Generated cell lines
were designated RDES/TR/shCtrl, RDES/TR/shCDS, RDES/TR/shUTR, SK-N-
MC/TR/shCtrl, SK-N-MC/TR/shCDS, SK-N-MC/TR/shUTR, TC32/TR/shCtrl,
TC32/TR/shCDS and TC32/TR/shUTR.
Gene expression microarray analysis and functional gene-set enrichment
analyses. To identify genes involved in cytokinesis in EwS, we used curated
publicly available gene expression data generated on Affymetrix HG-U133Plus2.0
DNA microarrays for 979 samples comprising 50 EwS tumor samples and 929
normal tissue samples (71 normal tissue types)12. First, differential gene expression
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and statistical significance levels were calculated with limma (R package,
v,3.44.3)37. Then, the resulting P-values were adjusted for multiple testing based on
false discovery rate (FDR) correction. Finally, only differentially expressed genes
with significant fold changes (FCs) (FDR-adjusted P < 0.05) were analyzed for Gene
Ontology (GO)-term enrichment using clusterProfiler (R package, v,3.16.1)38.
Annotation of GO-terms was done using the org.Hs.eg.db (R package, v,3.11.4).
To assess the impact of PRC1 on gene expression and on alternative splicing in
EwS, a microarray analysis was performed. To this end, 5 × 105 cells were seeded in
T25 flasks and treated with Dox for 60 h (Dox-refreshment after 48 h). Thereafter,
total RNA was extracted with the ReliaPrep miRNA Cell and Tissue Miniprep
System (Promega) and transcriptome profiled at IMGM laboratories (Martinsried,
Germany). RNA quality was assessed with a Bioanalyzer and samples with RNA
integrity numbers (RIN) > 9 were hybridized to Human Affymetrix Clariom D
microarrays. Data were quantile normalized with Transcriptome Analysis Console
(v4.0; Thermo Fisher Scientific) using the SST-RMA algorithm. Annotation of the
data was performed using the Affymetrix library for Clariom D Array (version 2,
human) on the gene level. DEGs with consistent and significant FCs across
shRNAs and cell lines were identified as follows: First, the normalized gene
expression signal was log2 transformed. To avoid false discovery artifacts due to the
detection of only minimally expressed genes, we excluded all genes with a lower or
just minimally higher gene expression signal than that observed for ERG (mean
log2 expression signal of 6.29), which is known to be virtually not expressed in
EWSR1-FLI1 positive EwS cell lines9. Accordingly, only genes with mean log2
expression signals (w/o Dox condition) of at least 6.5 were further analyzed. The
FCs of the shCtrl samples and both specific shRNAs were calculated for each cell
line separately. Then, the FCs observed in the respective shCtrl samples were
subtracted from those seen in the shPRC1 samples, which yielded the FCs for each
specific shRNAs in each cell line. Then these FCs were averaged to obtain the mean
FC per gene across shRNAs and cell lines. To identify enriched gene sets, genes
were ranked by their expression FC between the groups Dox (−/+), and a pre-
ranked gene-set enrichment analysis (GSEA) was done using fgsea (R package,
v,1.14.0) based on the biological processes GO definitions from MSigDB (v7.0,
c2.cgp.all)39,40. To visualize GSEA results (Supplementary Data 9), GO terms were
filtered for significance (adjusted P < 0.01; |Normalized enrichment score | >1.75)
and used to create a symmetric GO adjacency matrix based on the Jaccard distance
between GO terms and respective gene lists. GO clusters were identified using
dynamicTreeCut (R package, v.1.63.1), and the GO network was visualized in
Cytoscape (v.3.8.0)41.
Western blotting. EwS cells with Dox-inducible shRNAs were treated with Dox
(1 µg/ml for 72 h). To test for relative PRC1 protein expression levels across EwS
cell lines, EwS wt cells were cultured in standard culture conditions until reaching
70% confluence. Whole cellular protein was extracted using RIPA buffer containing
1 mM Na3VO4 and protease inhibitor cocktail (Sigma-Aldrich). Proteins were
separated on a 10% gel and blotted on PVDF membranes. Membranes were
incubated with rabbit polyclonal anti-PRC1 antibody (1:1000, 15617-1-AP, Pro-
teintech) or mouse monoclonal anti-GAPDH (1:800, sc-32233, Santa Cruz). Then,
membranes were incubated with horseradish peroxidase (HRP) coupled anti-rabbit
IgG (H+ L) (1:5,000, R1364HRP, OriGene) or anti-mouse IgG (H+ L) (1:3000,
W402B, Promega). Proteins were detected using chemiluminescence HRP substrate
(Millipore-Merck).
Proliferation assays. For proliferation assays, 2 × 105 EwS cells harboring Dox-
inducible shRNAs were seeded in wells of 6-well plates and treated with 1 µg/ml
Dox for 72 h (Dox-renewal after 48 h). Cell viability was determined by counting
cells including their supernatant in standardized hemocytometers (C-Chip, Bio-
chrom) via the Trypan-Blue (Sigma-Aldrich) exclusion method.
Clonogenic growth assays. For clonogenic growth assays, RDES, SK-N-MC, and
TC32 cells harboring Dox-inducible shRNAs against PRC1 and respective controls
were seeded at low density (300 cells) in triplicates in 12-well plates and grown for
12–16 days with the renewal of Dox (1 µg/ml) every 48 h. RDES and TC32 EwS
cells were seeded at low density (300 cells) in triplicates in 12-well plates and grown
for 12–16 days with the addition of BI2536 (5 nM) or BI6727 (20 nM) or DMSO on
day 1. Thereafter, colonies were stained with Crystal-Violet solution (Sigma-
Aldrich), and the number and size of colonies were measured with the ImageJ
Plugin Colony area. The clonogenicity index was calculated by multiplying the
number of colonies with the corresponding colony area.
Sphere-formation assays. For analysis of anchorage-independent growth, the
EwS cell lines RDES, SK-N-MC, and TC32 harboring shRNAs against PRC1 and
respective controls were seeded in wells at the density of 500 cells/well in 96-well
Costar Ultra-low attachment plates (Corning) in 80 µl standard cell culture med-
ium with/without Dox (1 µg/ml) and incubated for 14 days. RDES and TC32 EwS
cells were seeded in wells at the density of 500 cells/well in 96-well Costar Ultra-low
attachment plates (Corning) in 80 µl standard cell culture medium with addition of
BI2536 (5 nM) or BI6727 (20 nM) or DMSO on day 1. The CRISPR-Cas9 edited
A673 EwS cell lines and its wide type cells were seeded in wells at the density of 300
cells/well in 96-well Costar Ultra-low attachment plates (Corning) in 80 µl standard
cell culture medium. Ten microliters of fresh medium were added every 48 h. On
day 14, wells were photographed, and sphere numbers and diameters were ana-
lyzed using ImageJ using the formula Area= π × A × B/4 (with A and B referring to
orthogonal diameters).
Cell cycle and apoptosis analysis. For analysis of cell cycle, RDES, SK-N-MC,
and TC32 cells harboring a Dox-inducible shRNA against PRC1 and respective
controls were synchronized by a double thymidine (T1850, Sigma-Aldrich) block/
release42. Briefly, cells were blocked in G1/S with 1 mM thymidine for 18 h at 37 °C,
then released into the S phase by washing 3× with pre-warmed serum-free media.
A fresh complete medium was added to the cells and incubated for 10 h at 37 °C.
The second round of thymidine to a final concentration of 1 mM was added and
cells were cultured for another 18 h at 37 °C. Cells were in the G1/S boundary by
then. After washing 3× with pre-warmed serum-free media, cells were seeded at
5 × 105 cells per T25 flask in the fresh medium with/without the addition of Dox
(1 µg/ml). Dox was renewed 48 h after seeding. Cells were fixed with ice-cold 70%
ethanol at each time point post releasing (24 h, 48 h, and 72 h), treated with 100 µg/
ml RNAse (ThermoFisher), and stained with 50 µg/ml propidium iodide (PI)
(Sigma-Aldrich). For analysis of apoptosis, RDES, SK-N-MC, and TC32 cells
harboring a Dox-inducible shRNA against PRC1 and respective controls were
seeded at 8 × 105 cells per 10 cm dish with/without the addition of Dox (1 µg/ml)
for 72 h. Dox was renewed 48 h after seeding. RDES and TC32 EwS cells were
seeded at 8 × 105 cells per 10 cm dish with/without the addition of PLK1 inhibitor
BI2536 (5 nM) or BI6727 (20 nM) or DMSO. For time-lapse apoptosis analysis,
RDES and TC32 cells harboring a Dox-inducible shRNA against PRC1 and
respective controls were seeded at 8 × 105 cells per 10 cm dish with/without the
addition of Dox (1 µg/ml) and analyzed at different time points after shRNA-
mediated knockdown (24 h and 48 h). The CRISPR Cas9-initiated HDR edited
A673 EwS cells and A673 wt cells were seeded at 1 × 106 cells per 10 cm dish and
analyzed 24 h after seeding. Analysis of apoptosis has been performed at indicated
time points by combined Annexin V-FITC/PI staining (BD Pharmingen FITC
Annexin V Apoptosis Detection Kit II). Samples were assayed with BD Accuri C6
Cytometer (BD Biosciences). An example of a gating strategy was given in Sup-
plementary Fig. 7.
Fluorescence-in-situ-hybridization (FISH). After shRNA-induced PRC1 knock-
down for 48 h, EwS cells with ~70% confluency were incubated for 6 h with 0.2 mg/
ml colcemid (Demecolcine Solution D1925 Sigma 10 µg/ml in HBSS). Meta-phase
cells were harvested by trypsinizing, treated with a pre-warmed hypotonic solution
(75 mM KCl) for 30 min at 37 °C, and fixed in fresh, ice-cold 3:1 methanol:acetic
acid solution for 3 × 15 min. The fixed cells were kept overnight at 4 °C. Frozen
slides were brought to RT on a heating plate. 20 µl of fixed cell suspension was
dropped onto pre-cold clean slides and allowed to air-dry overnight. For chro-
mosome counts, the cells were incubated with a pan-centromere probe coupled
with fluorescein isothiocyanate (FITC) dye (Star*FISH, 1695-F-02, Cambio, UK)
following the manufacturer’s instructions with modifications. Briefly, to remove the
acid, slides were passed through a graded alcohol series 70, 90, 100% for 2 min and
allowed to air dry. Slides were then baked at 65 °C for 15 min and cooled to RT,
and washed in acetone for 10 min and again air-dried. RNase was diluted in 2×
standard saline concentration (SSC) (0.3 M sodium chloride, 0.03M sodium
citrate, pH7) to a final concentration of 100 µg/ml and added to the slides for 1 h at
37 °C in a humidified box. After washing the slides two times in 2× SSC for 5 min
and two times for 5 min in 1× phosphate-buffered saline (PBS), the slides were
immersed in a pepsin solution (100 ng/ml, pH2) for 3 min at 37 °C. Thereafter,
slides were fixed in 4% paraformaldehyde for 4 min at 37 °C. After another washing
step in 1× PBS for 5 min, the slides were dehydrated in 70, 90 and 100% ethanol at
RT and allowed to air dry. The slides were denatured for 2 min in 70% formamide,
2× SSC, pH7, at 70 °C, and dehydrated immediately in ice-cold 70% ethanol for
2 min. After dehydrating in 70, 90, and 100% ethanol, slides were air-dried for
30 min. The pan-centromere probe was denatured for 10 min at 85 °C and
immediately chilled on ice. 10 µl of the probe were added to the slides. The slides
were covered with a coverslip and sealed with rubber cement. Hybridization was
carried out overnight at 37 °C. After removing the coverslips, the slides were
washed in 2× SSC for 5 min and fixed in 50% formamide/2× SSC (pH7; 37 °C) two
times for 5 min and then rinsed in 2× SSC two times for 5 min. The FITC-labeled
probe was detected with 100 µl rabbit anti-FITC (1:200) in 4× SSC/0.1% Tween20
for 30 min at 37 °C in a humidified box. Afterward, slides were washed three times
for 4 min in 4× SSC/0.1% Tween20. The signals were enhanced by FITC goat-anti-
rabbit IgG (1:100) in 4× SSC/0.1% Tween20 for 30 min at 37 °C in a humidified
box. After washing three times in 4XSSC/0.1% Tween20 for 4 min, the cells were
counterstained with 4,6-diamidino-2 phenylindol/propidium iodide (DAPI) and
embedded in the antifade solution. Slides were kept in dark at 4 °C. Analysis was
carried out using a fluorescence microscope (Zeiss AxioVision MC 50, 100W HBO
lamp) with a triple dye filter for the detection of DAPI, propidium iodide, and
FITC. Images were captured using AxioVision 4.9 software, and when necessary,
signals were enhanced for optimal contrast using Adobe Photoshop 2020.
Approximately 200 nuclei were evaluated in each set from at least 3 independent
experiments (at least 35 nuclei). Inter-line variability of chromosome number was
estimated on nuclei with a number of centromere signals different from the modal
number of signals according to the composite karyotype of each cell line. The
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karyotypic changes were classified and quantified according to the International
Standard of Cytogenetic Nomenclature (ISCN)43 and as previously described44:
aneuploidy (chromosome loss/gain), non-congressed, multipolar, and,
monster’ cells.
Time-lapse live-cell imaging. TC32 and RDES EwS cells harboring a Dox-
inducible shRNA against PRC1 were seeded on coated Ibidi μ-slide 8 well (Ibidi
GmbH, Germany) (chamber) slides at 300 μl/well (6 × 104 cells) and incubated at
37 °C for 48 h with/without Dox (1 µg/ml) to allow for PRC1 knockdown. On the
day of imaging, cells were washed 3× with prewarmed FluoroBrite™ DMEM
(A1896701, Life Technologies) and then stained for 30 min with 1× CellMask™
Deep Red Acting Tracking Stains (A57245, Life Technologies) in 250 μl Live Cell
Imaging Solution (A14291DJ, Invitrogen). The staining solution was then carefully
removed and the cells were subsequently counterstained with Hoechst 33342 Ready
Flow Reagent (RF001, Invitrogen) for 15 min in the dark at 37 °C. After exposure,
cells were washed 3× with Live Cell Imaging Solution at 37 °C and then imaged and
analyzed in 300 µl prewarmed FluoroBrite™ DMEM (A1896701, Life Technologies)
supplemented with 10% FCS, 4 mM GlutaMax (Invitrogen), and 20 mM HEPES
(Invitrogen). The environment throughout imaging was controlled at 37 °C, 5%
CO2, and 90% humidity. Time-lapse images were acquired with an inverted Zeiss
Axio Observer Z1 widefield microscope equipped with a piezoelectric focus and an
AxioCam MRm grayscale CCD camera and controlled by ZEN pro software
(Zeiss). Brightfield, Cy5 (AHF F36-523), and DAPI (Zeiss Filter Set 49, 488049-
9901-000) were captured using a ×40 oil, 1.4 numerical aperture (NA) objective
combined with 2 × 2 binning modes. Fluorescence and bright-filed images were
acquired as Z-stacks (10 planes, 2 μm interval) in 2 × 2 binning modes at 15–20
random positions every 30 min for 18 h per condition. The resulting images were
processed, analyzed, and colored using ZEN pro (Zeiss) software. When necessary,
signals were enhanced for optimal contrast using Adobe Photoshop 2020. The
percentage of mitotic cells that exited mitosis as a single cell was reported as those
that fail cytokinesis.
In vivo experiments. NOD/Scid/gamma (NSG) mice have been housed in indi-
vidually ventilated cages (IVC) under specific pathogen-free (SPF) conditions with
strict dark/light cycles (darkness from 6 p.m. to 6 a.m.), an ambient temperature of
21–23 °C and a humidity of 45–65%. 5 × 106 EwS cells harboring an shRNA against
PRC1 or a non-targeting control shRNA were injected in a 1:1 mix of cells sus-
pended in HBSS formulated with Calcium and Magnesium (ThermoFisher) in the
right flank of 10–12 weeks old NSG mice. Both tumor diameters were measured
every second day with a caliper and tumor volume was calculated by the formula
(L × l2)/2. When the tumors reached an average volume of ~100 mm3, mice were
randomized in two groups of which one henceforth was treated with 2 mg/ml
BelaDox (Bela-pharm) dissolved in drinking water containing 5% sucrose (Sigma-
Aldrich) to induce an in vivo knockdown, whereas the other group only received
5% sucrose (control). Once tumors in the control group exceeded a volume of
1500 mm3, all mice were sacrificed by cervical dislocation. Other humane end-
points were determined as follows: Ulcerated tumors, loss of ≥20% body weight,
constant curved or crouched body posture, bloody diarrhea or rectal prolapse,
abnormal breathing, severe dehydration, visible abdominal distention, obese Body
Condition Scores (BCS), apathy, and self-isolation.
For in vivo experiments using PLK1 inhibitors, 5 × 106 CRISPR Cas9-initiated
HDR edited PRC1-associated mSat KO A673 cells and CRISPR Cas9-edited
negative control (NC) cells were subcutaneously injected in mice as described
above. When the tumors reached an average volume of ~100 mm3, mice were
randomly distributed in equal groups and henceforth treated once per week
intravenously (i.v.) with 40 mg/kg BI2536, 30 mg/kg BI6727 (Volasertib), or vehicle
(0.1 N HCI with 0.9% saline) for 3–4 treatment weeks. At the experimental
endpoint or if humane endpoints as described above were reached before, mice
were sacrificed by cervical dislocation. Then, xenograft tumors were extracted and
fixed in 4%-formalin and paraffin-embedded (FFPE) for (immuno)histology.
For in vivo experiments using VCR and/or the PLK1 inhibitor BI6727 as a
single agent or in combination, 5 × 106 TC32 EwS cells were subcutaneously
injected in mice as described above. When the tumors reached an average volume
of ~100 mm3, mice were randomly distributed in equal groups and henceforth
treated with vehicle (0.1N HCI with 0.9% saline), VCR (alone i.p. [1 mg/kg/d] on
days 0 and 1 of treatment), BI6727 (Volasertib; alone, i.v. [5 mg/kg] on day 0 of
treatment), or VCR (i.p. [1 mg/kg/d] on days 0 and 1 of treatment) plus BI6727
(Volasertib; i.v. [5 mg/kg] on day 0 of treatment) for 4 treatment-cycles. At the
experimental endpoint or if humane endpoints as described above were reached
before, mice were sacrificed by cervical dislocation. Then, xenografted tumors were
extracted and fixed in 4%-formalin and paraffin-embedded (FFPE) for (immuno)
histology. Animal experiments were approved by the governments of Upper
Bavaria and Northbaden and conducted in accordance with ARRIVE guidelines,
recommendations of the European Community (86/609/EEC), and UKCCCR
(guidelines for the welfare and use of animals in cancer research).
Human samples and ethics approval. Human FFPE tissue samples were retrieved
from the archives of the Institute of Pathology of the LMU Munich (Germany) and
the Gerhard-Domagk Institute of Pathology of the University of Münster
(Germany) with approval of the institutional review boards. All patients gave
informed consent. Tissue-microarrays (TMAs) were stained and analyzed with the
approval of the ethics committee of the LMU Munich (approval no. 550-16 UE).
Immunohistochemistry (IHC) and immunoreactivity scoring. For IHC, 4-μm
FFPE sections were cut and antigen retrieval was carried out by heat treatment with
Target Retrieval Solution (S1699, Agilent Technologies). The slides were stained
with either polyclonal anti-PRC1 antibody raised in rabbit (1:200, 15617-1-AP,
Proteintech), monoclonal anti-γ-H2AX raised in rabbit (1:8000, ab81299, Abcam),
or with monoclonal anti-Ki-67 raised in rabbit (1:200, 275R-15, Cell Marque) for
60 min at RT, followed by a monoclonal secondary horseradish peroxidase (HRP)-
coupled horse-anti-rabbit antibody (ImmPRESS Reagent Kit, MP-7401, Vector
Laboratories) or for 120 min at RT followed by Dako REAL™ Detection kit,
Alkaline Phosphatase/RED Rabbit/Mouse (K5005, Dako). AEC-Plus (K3461,
Agilent Technologies) or Substrate RED (K5005, Dako) was used as chromogen in
the corresponding detection system. Samples were counterstained with hematox-
ylin (H-3401, Vector Laboratories and T865.1 Roth). For cleaved caspase-3 (CC3)
staining, antigen retrieval was carried out by heat treatment with Target Retrieval
Solution Citrate pH6 (S2369, Agilent Technologies). Slides were incubated with the
polyclonal CC3 primary antibody raised in rabbit (1:100; 9661, Cell Signaling) for
60 min at RT followed by ImmPRESS Reagent Kit (MP-7401, Vector Laboratories)
or for 120 min at RT followed by Dako REAL™ Detection kit, Alkaline Phospha-
tase/RED Rabbit/Mouse (K5005, Dako). DAB+(K3468, Agilent Technologies) or
Substrate RED (K5005, Dako) was used as chromogen in the corresponding
detection system and hematoxylin for counterstaining. For human mitochondrial
staining, antigen retrieval was carried out by heat treatment with Pro Taqs II
Antigen Enhancer (401602192, Quartett). Slides were incubated with the mono-
clonal anti-human mitochondria antibody raised in mouse (1:1,000; ab92824,
Abcam) for 60 min at RT followed by ImmPRESS Reagent Kit (MP-7402, Vector
Laboratories). AEC-Plus (K3461, Agilent Technologies) was used as the chromo-
gen. For CD99 staining, slides were stained with monoclonal anti-human CD99
antibody raised in mouse (1:40, ab8855, Abcam) for 32 min using the ultraView
detection kit in a VENTANA BenchMark system (Roche, Basel, Switzerland), and
counterstained with hematoxylin.
To assess tissue integrity and for detection of mitotic defects, e.g., monster’ cells,
FFPE blocks of EwS xenografts were stained with hematoxylin and eosin (H&E).
Evaluation of PRC1 immunoreactivity was carried out in analogy to the scoring of
hormone receptor Immune Reactive Score (IRS) ranging from 0–12. This modified
IRS scoring scheme has been adapted to EwS and has been described and validated
previously12,18,45–47. The percentage of cells with expression of the given antigen
was scored and classified in five grades (grade 0= 0–19%, grade 1= 20–39%, grade
2= 40–59%, grade 3= 60–79%, and grade 4= 80–100%). In addition, the intensity
of marker immunoreactivity was determined (grade 0= none, grade 1= low, grade
2=moderate, and grade 3= strong). The product of these two grades defined the
final IRS. Evaluation of Ki-67, CC3, and γ-H2AX immunoreactivity was quantified
based on their positive staining percentage of cells per high-power field (HPF).
Final scores were determined by examination of 5–15 HPFs of at least one section
per sample.
Drug-response assays and drug combination analysis. For PLK1 inhibitor
treatment, 5000 cells/well of Dox-inducible shRNA expressing RDES and TC32
EwS cells were seeded in triplicate wells of 96-well plates. Cells were pre-treated for
48 h with Dox to induce the PRC1 knockdown before the addition of BI2536
(S1109, Selleckchem) or BI6727 (Volasertib; S2235, Selleckchem). Cells were then
treated with 0–1000 nM BI2536 or BI6727 (Volasertib) with/without Dox for an
additional 72 h. The same assays were carried out with wt and CRISPR Cas9-
initiated HDR edited A673 cell with a pre-incubation time of only 24 h to permit
surface adherence. At the experimental endpoint, cell growth inhibition was
assessed using a Resazurin assay (Sigma-Aldrich) with careful adaptations to EwS
cells48. It should be noted that the dye Resazurin can induce fluorescence emission
only in viable cells48. The relative IC50 concentrations were calculated using
PRISM 8 (GraphPad Software Inc., CA, USA) and normalized to the respective
DMSO controls.
For drug combination assays, 5000 cells of Dox-inducible shRNA expressing
RDES and TC32 EwS cells were seeded in triplicate wells of 96-well plates. Cells
were pre-treated for 48 h with Dox to induce the PRC1 knockdown. Then, cells
were treated with 0–100 nM PLK1 inhibitor, 0–4 nM Vincristine (VCR), and/or
0–100 nM Doxorubicin (Doxo). Inhibition of cell growth was assessed 72 h after
the start of the treatment using a Resazurin assay. The excess over Bliss was
calculated using synergyfinder (R package v.2.2.4)49. For assessment of the dose
reduction index (DRI), 5000 cells/well of RDES and TC32 EwS cells were seeded in
triplicate wells of 96-well plates 24 h before the addition of PLK1 inhibitors. Cells
were treated with 0–100 nM PLK1 inhibitor, 0–4 nM VCR alone or in combination
in a 1:1 constant combination ratio50. Inhibition of cell growth was assessed 72 h
after the start of the treatment using a Resazurin assay. CompuSyn (ComboSyn,
Inc.) was used for determining the DRI of each PLK1 inhibitor at the IC50 level.
For Doxo-resistance reversal assays, non-toxic concentrations (<IC10) of PLK1
inhibitors BI2536 or BI6727 in two Doxo-res EwS cell lines (A673 Doxo-res; TC71
Doxo-res) were determined by a Resazurin assay after PLK1 inhibition
(0–1000 nM) for 72 h, respectively. In Doxo-resistant cell lines, the differential
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in vitro efficacy of Doxo depending on the co-treatment with PLK1 inhibitor
BI2536 or BI6727 was assessed by a Resazurin assay. To this end, cells were treated
for 72 h with different concentrations of Doxo (0–2000 nM) and co-treated with
the non-toxic dosage of PLK1 inhibitor BI2536 or BI6727 (10 nM) as defined
above. The predicted ED50 concentrations were calculated using CompuSyn
(ComboSyn, Inc.). For both cell lines, the reverse index (RI) was calculated by
dividing the ED50 of Doxo alone by the ED50 of the combination treatment (Doxo
plus 10 nM of PLK1 inhibitor).
Statistical analyses. If not otherwise specified, statistical data analysis was performed
using PRISM 8 (GraphPad Software Inc., CA, USA) on the raw data. If not otherwise
specified in the figure legends comparison of two groups in functional in vitro
experiments was carried out using a two-sided Mann-Whitney test. Contingency tables
of FISH counting were analyzed by the Chi-square or Fisher’s exact test as appropriate.
Pearson correlation analysis was done and visualized using the R package ggpubr
(v,0.4.0). If not otherwise specified in the figure legends, data are presented as box-dot
plots with horizontal bars representing means and whiskers representing the standard
error of the mean (SEM). The sample size for all in vitro experiments was chosen
empirically. For in vivo experiments, the sample size was predetermined using power
calculations with β= 0.8 and α < 0.05 based on preliminary data and in compliance
with the 3R system (replacement, reduction, refinement). In retrospective Kaplan-Meier
analyses of overall survival, curves were calculated from all individuals. Statistical dif-
ferences between the groups were assessed by a Mantel-Haenszel test. The sample sizes
of the patient cohorts were not predetermined. Retrospective analysis of survival
probabilities was done on an exploratory basis. Cox multivariate statistical analyses were
carried out in IBM SPSS Statistics software (version 23.0; IBM Corp). A hazard ratio
(HR) > 1 indicated that patients were at risk of a worse prognosis. Potential associations
of the STAG2 and/or TP53 mutation status with PRC1 expression levels were assessed
by a two-sided Fisher’s exact test in 57 ICGC EwS cases for which the mutation status
and transcriptome profiles were available51. To develop a prognostic index (PI), EwS
patients were first stratified into two groups (i.e., PRC1-high and PRC1-low, and PLK1-
high and PLK1-low expression) using the median cut-off of the expression level for each
gene. The PI of every patient was calculated as the sum of each gene score, which was
calculated by multiplying the expression level of a gene by its corresponding coefficient
(i.e., PI=∑ Cox coefficient of gene Gi × expression level of gene Gi). Subsequently,
patients were stratified into three PI groups (i.e., low, moderate, and high) by thirds of
the calculated PI as cut-offs. Kaplan-Meier analysis was performed and the difference in
survival time between the lowest and highest third was assessed using a Mantel-
Haenszel test. P-values < 0.05 were considered statistically significant. If not otherwise
specified in the figure legends, all P-values were estimated from two-sided
statistical tests.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The microarray data were deposited at the National Center for Biotechnology
Information (NCBI) GEO database under the accession code GSE156559. The
microarray, DNase-Seq, and ChIP-Seq data referenced during the study are available in a
public repository from the GEO website (https://www.ncbi.nlm.nih.gov/geo/); accession
codes: GSM736570 and GSE61944. The relative PRC1 protein expression data in EwS cell
lines were extracted from Proteomics (O43663) dataset derived from DepMap portal
(https://depmap.org/portal/). The PRC1, PLK1, and MKI67 mRNA expressions of 11
EwS cell lines were extracted from the Expression 21Q public dataset and their
corresponding drug sensitivities toward PLK1 inhibitor BI6727 (Volasertib) treatment
were extracted from the PRSIM Repurposing Primary Screen 19Q4 derived from
DepMap portal (https://depmap.org/portal/). The source data underlying Fig. 1a–c, 2a–g,
3a–j, 4a–j, and Supplementary Figs. 1, 2b–i, 3a–g, 4a–l, 5a–e, 6a, b are provided as a
Source Data file. All the other data supporting the findings of this study are available
within the article and its supplementary information files. Source data are provided with
this paper.
Code availability
All custom codes supporting the findings of this study are available from the
corresponding author upon reasonable request.
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